MatthewSDavidsMDMMSc

PubMed

• An indirect comparison of acalabrutinib with and without obinutuzumab versus zanubrutinib in treatment-naive CLL.
  John N Allan, Dan James, Helen Bridge, Miguel Miranda, Alan Sm Yong, Fady Fam, Jack Roos, Vikram Shetty Dr, Adam S Kittai, Alan P Skarbnik, Matthew S Davids> ;Blood Advances. 2024 Apr 10
• Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study.
  Adam S Kittai, David Bond, Ying Huang, Seema A Bhat, Emily Blyth, John C Byrd, Julio C Chavez, Matthew S Davids, Jamie P Dela Cruz, Mark R Dowling, Caitlyn Duffy, Carr...> ;Journal of Clinical Oncology. 2024 Mar 29
• A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia.
  Paul Joseph Hampel, Kerry A Rogers, Wei Ding, Saad S Kenderian, Sameer A Parikh, Mahesh Swaminathan, Erin M Parry, Jan A Burger, Matthew S Davids, Alessandra Ferrajoli...> ;Blood Advances. 2024 Mar 27
• Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.
  Herling, M., Dearden, C., Zaja, F., El-Sharkawi, D., Ding, W., Bellido, M., Khot, A., Tick, L., Jacobsen, E., Eyre, T., Roos-Weil, D., Kadia, T., Lucchini, E., Pflug, ...> ;Blood Advances. 2024 Feb 27
• Five-year follow-up of a phase 2 study of ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial therapy in CLL.
  Ahn, I., Brander, D., Ren, Y., Zhou, Y., Tyekucheva, S., Walker, H., Black, R., Montegaard, J., Alencar, A., Shune, L., Omaira, M., Jacobson, C., Armand, P., Ng, S., C...> ;Blood Advances. 2024 Feb 27
• Therapeutic targeting of apoptosis in chronic lymphocytic leukemia.
  Inhye E Ahn, Matthew S Davids> ;Seminars in Hematology. 2024 Feb 7
• Highlights in chronic lymphocytic leukemia from the 65th ASH Annual Meeting and Exposition: commentary.
  Matthew S Davids> ;Clinical Advances in Hematology & Oncology. 2024 Feb 1
• Six-year follow-up and subgroup analyses of a phase 2 trial of venetoclax for del(17p) chronic lymphocytic leukemia.
  Stephan Stilgenbauer, Eugen Tausch, Andrew W Roberts, Matthew S Davids, Barbara Eichhorst, Michael Hallek, Peter Hillmen, Christof Schneider, Johannes Schetelig, Sebas...> ;Blood Advances. 2024 Apr 23
• Mutations Detected in Real World Clinical Sequencing during BTK Inhibitor Treatment in CLL.
  Mashima, K., Fernandes, S., Naeem, A., Shupe, S., Fardoun, R., Brown, J., Davids, M.> ;Research Square. 2024 Jan 16
• Overcoming Resistance in Chronic Lymphocytic Leukemia-Maybe Less Is More?
  Al-Sawaf, O., Davids, M.> ;Clinical Cancer Research. 2024 Feb 1
• 1 citations
  Pirtobrutinibvenetoclax in covalent Bruton tyrosine kinase inhibitor-pretreated chronic lymphocytic leukemia: a matching-adjusted indirect comparison.
  Othman Al-Sawaf, Min-Hua Jen, Lisa M Hess, Jiewen Zhang, Benjamin Goebel, John M Pagel, Sarang Abhyankar, Matthew S Davids, Toby A Eyre> ;Haematologica. 2023 Nov 30
• Functional cure reported in CLL.
  Matthew S Davids> ;Blood. 2023 Nov 23
• 2 citations
  First-in-Human Study with Preclinical Data of BCL-2/BCL-xL Inhibitor Pelcitoclax in Locally Advanced or Metastatic Solid Tumors.
  Nehal J Lakhani, Drew Rasco, Hengbang Wang, Lichuang Men, Eric Liang, Tommy Fu, Mary C Collins, Ping Min, Yan Yin, Matthew S Davids, Dajun Yang, Yifan Zhai> ;Clinical Cancer Research. 2024 Feb 1
• A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed/refractory follicular lymphoma.
  Reid W Merryman, Robert A Redd, Arnold S Freedman, Inhye E Ahn, Jennifer R Brown, Jennifer L Crombie, Matthew S Davids, David C Fisher, Eric D Jacobsen, Austin I Kim, ...> ;Annals of Hematology. 2024 Jan 1
• 4 citations
  Hyperphosphorylation of BCL-2 family proteins underlies functional resistance to venetoclax in lymphoid malignancies.
  Stephen Jun Fei Chong, Fen Zhu, Olga Dashevsky, Rin Mizuno, Jolin Xh Lai, Liam Hackett, Christine E Ryan, Mary C Collins, J Bryan Iorgulescu, Romain Guièze, Johany Pen...> ;The Journal of Clinical Investigation. 2023 Nov 15
• 55 citations
  PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer.
  Antonino Glaviano, Aaron S C Foo, Hiu Y Lam, Kenneth C H Yap, William Jacot, Robert H Jones, Huiyan Eng, Madhumathy G Nair, Pooyan Makvandi, Birgit Geoerger, Matthew H...> ;Molecular Cancer. 2023 Aug 18
• 2 citations
  Hypomethylating agent decitabine sensitizes diffuse large B-cell lymphoma to venetoclax.
  Fen Zhu, Jennifer L Crombie, Wei Ni, Nguyet-Minh Hoang, Swati Garg, Liam Hackett, Stephen J F Chong, Mary C Collins, Lixin Rui, James Griffin, Matthew S Davids> ;Haematologica. 2024 Jan 1
• Management of Richter transformation.
  Matthew S Davids> ;Clinical Advances in Hematology & Oncology. 2023 Aug 1
• Targeting conditioned media dependencies and FLT-3 in chronic lymphocytic leukemia.
  Salma Parvin, Aditi Aryal, Shanye Yin, Geoffrey G Fell, Matthew S Davids, Catherine J Wu, Anthony Letai> ;Blood Advances. 2023 Oct 10
• 13 citations
  Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance.
  Aishath Naeem, Filippo Utro, Qing Wang, Justin Cha, Mauno Vihinen, Stephen Martindale, Yinglu Zhou, Yue Ren, Svitlana Tyekucheva, Annette S Kim, Stacey M Fernandes, Go...> ;Blood Advances. 2023 May 9
• 2 citations
  Genetic events associated with venetoclax resistance in CLL identified by whole-exome sequencing of patient samples.
  Jasneet Kaur Khalsa, Justin Cha, Filippo Utro, Aishath Naeem, Ishwarya Murali, Yanan Kuang, Kevin Vasquez, Liang Li, Svitlana Tyekucheva, Stacey M Fernandes, Lauren Ve...> ;Blood. 2023 Aug 3
• 3 citations
  Novel BCL-2 Inhibitor Lisaftoclax in Relapsed or Refractory Chronic Lymphocytic Leukemia and Other Hematologic Malignancies: First-in-Human Open-Label Trial.
  Sikander Ailawadhi, Zi Chen, Bo Huang, Aneel Paulus, Mary C Collins, Lei Tommy Fu, Mingyu Li, Mohammad Ahmad, Lichuang Men, Hengbang Wang, Matthew S Davids, Eric Liang...> ;Clinical Cancer Research. 2023 Jul 5
• 3 citations
  Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study.
  Mazyar Shadman, Beenish S Manzoor, Kavita Sail, Hande H Tuncer, John N Allan, Chaitra Ujjani, Nnadozie Emechebe, Rajesh Kamalakar, Catherine C Coombs, Lori Leslie, Pau...> ;Clinical Lymphoma, Myeloma & Leukemia. 2023 Jul 1
• 8 citations
  In Vivo Modeling of CLL Transformation to Richter Syndrome Reveals Convergent Evolutionary Paths and Therapeutic Vulnerabilities.
  Ten Hacken, E., Sewastianik, T., Yin, S., Hoffmann, G., Gruber, M., Clement, K., Penter, L., Redd, R., Ruthen, N., Hergalant, S., Sholokhova, A., Fell, G., Parry, E., ...> ;Blood Cancer Discovery. 2023 Mar 1
• Circulating Th17 T cells at treatment onset predict autoimmune toxicity of PI3Kδ inhibitors.
  Deepti Gadi, Stephen P Martindale, Pui Yan Chiu, Jasneet Khalsa, Pei-Hsuan Chen, Stacey M Fernandes, Zixu Wang, Svitlana Tyekucheva, John-Hanson Machado, David C Fishe...> ;Blood Cancer Journal. 2023 Feb 2
• Join now to see all

Journal Articles

• The Phase 3 DUO Trial: Duvelisib Versus Ofatumumab in Relapsed and Refractory CLL/SLL  
  Matthew S Davids, Ian W Flinn, Craig A Portell, Nicole Lamanna, Scott Lunin, Amanda F Cashen, Blood

Abstracts/Posters

• Outcomes of Ibrutinib (Ibr) Therapy in Ibr-Na¥ve Patients (pts) with Chronic Lymphocytic Leukemia (CLL) Progressing after Venetoclax (Ven)
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Le...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Ongoing Results of a Phase 1B/2 Dose-Escalation and Cohort-Expansion Study of the Selective, Noncovalent, Reversible BrutonÍS Tyrosine Kinase Inhibitor, Vecabrutinib, ...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• An Innovative Telemedicine Platform to Provide Expert Access to Patients with Chronic Lymphocytic Leukemia (CLL)
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• A Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL / SLLA Phase I Study of Duvelisib and Venetoclax in Patients with Relapsed or R...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Early Adoption and Outcomes of Ibrutinib As Treatment for Older Patients with Chronic Lymphocytic Leukemia (CLL): A Population-Based Study
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Clinical and Immunologic Activity of Ipilimumab Following Decitabine Priming in Post-Allogeneic Transplant and Transplant-Na¥ve Patients with Relapsed or Refractory My...
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• High Sensitivity NGS Analysis of MRD in CLL Patients Prospectively Treated with Ibrutinib Plus FCR (iFCR)
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Identification of Genotype-Specific Therapeutic Vulnerabilities By Comparative Dynamic BH3 Profiling Analysis of Human and Murine CLL
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• MCL-1 and PKA/AMPK Axis Fuel Venetoclax Resistance in Lymphoid Cancers
  Matthew S. Davids, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
• Join now to see all

Lectures

• Cost-Effectiveness of a 12-Month Fixed Duration of Venetoclax in Combination with Obinutuzumab in First-Line Chronic Lymphocytic Leukemia in the United States 
  61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
• Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical and Biological Indicators of Duvelisib Efficacy in CLL from the Phase 3 DUOTM Study 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Pha... 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Mitigation of tumor lysis syndrome (TLS) complications with venetoclax (VEN) in CLL. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• Join now to see all

Other

• The Rise of Apoptosis: Targeting Apoptosis in Hematologic Malignancies 
  Matthew Davids, MD, Blood
  https://www.doximity.com/articles/98c8dcba-e43a-4f7a-a7f7-4f3bd29ea5d9
  UpToDate, Wolters Kluwer Health - 2013-03-29